# Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension

Study · id `cardio:ct-nct01237223` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01237223](<https://clinicaltrials.gov/study/NCT01237223>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01237223

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1342 participants.

## Technical summary

Registry record NCT01237223. Randomized; double masking; primary purpose treatment. Start 2010-10 (registry gives no type); primary completion 2011-05 (actual). Results posted on 2012-06-13.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1342 participants (enrolled count; ClinicalTrials.gov record NCT01237223, source copy `cardio:ctgov-nct01237223-2012-06-13`, retrieved 2026-10-26)
- Start date: 2010-10 (registry gives no type) (ClinicalTrials.gov record NCT01237223, source copy `cardio:ctgov-nct01237223-2012-06-13`, retrieved 2026-10-26)
- Primary completion: 2011-05 (actual) (ClinicalTrials.gov record NCT01237223, source copy `cardio:ctgov-nct01237223-2012-06-13`, retrieved 2026-10-26)
- Completion: 2011-05 (actual) (ClinicalTrials.gov record NCT01237223, source copy `cardio:ctgov-nct01237223-2012-06-13`, retrieved 2026-10-26)
- Results first posted: 2012-06-13 (ClinicalTrials.gov record NCT01237223, source copy `cardio:ctgov-nct01237223-2012-06-13`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT01237223, source copy `cardio:ctgov-nct01237223-2012-06-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01237223-2012-06-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension
- Condition: Essential Hypertension
- Intervention (Drug): Aliskiren/Amlodipine 150/2.5 mg
- Intervention (Drug): Aliskiren/amlodipine 150/5 mg
- Intervention (Drug): Aliskiren 150 mg
- Intervention (Drug): Amlodipine 2.5 mg
- Intervention (Drug): Placebo of Aliskiren
- Intervention (Drug): Placebo of Amlodipine
- Intervention (Drug): Placebo of Aliskiren/amlodipine 150/2.5 mg
- Intervention (Drug): Placebo of Aliskiren/amlodipine 150/5 mg
- Lead sponsor: Novartis
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

## Provenance

Content hash: 950c87463c0004a8c8cd079092b796873d9f220d28ab87234cf0688633fc1647
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
